Browse
Submit Data
Databases
API
Help

Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

BRBseq of human skin-derived precursor hepatic progenitor-like cells with varying polygenic risk score for hepatic fat content exposed in vitro to vehicle-matched control medium or triggers related to MASH

ABSTRACT: 92 human skin-derived precursor (hSKP) cell lines, isolated from unique donors, were genotyped for the following SNPs that have been linked to metabolic dysfunction-associated steatotic liver disease (MASLD) onset and progression: PNPLA3 rs738409 C>G, TM6SF2 rs58542926 C>T, GCKR rs1260326 C>T and MBOAT7 rs641738 C>T. Based on carriage of these SNPs, the polygenic risk score for hepatic fat content (PRS-HFC) was calculated for each cell line and used for classification in either a low, intermediate or high risk category. From the low and high risk category, five cell lines were selected and differentiated to hepatic progenitor-like cells (hSKP-HPCs) before exposing the cells for 24 hours to either vehicle-matched control medium or a mixture of MASH-related triggers including sodium oleate, palmitic acid, fructose, lipopolysaccharide and tumour necrosis factor alpha. Total RNA was extracted from the cells and processed for bulk RNA barcoding and sequencing (BRBseq) as described by Alpern and colleagues (2019).

INSTRUMENT(S): Illumina NovaSeq 6000

ORGANISM(S): Homo sapiens

SUBMITTER: Alexandra Gatzios

PROVIDER: E-MTAB-15891 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Similar Datasets

Sex- and hepatocyte Pparg-dependent hepatic effects of a high fat diet containing 60% kcal from fat and 2% cholesterol, which was supplemented with 10% fructose in the drinking water (HFC+Fr) to induce diet-induced obesity in male and female mice.

Project description:Most western diets or Amilyn-based diets induce MASLD and MASH in mice but do not fully reproduce metabolic dysfunction in male and female mice. In this study, a high fat diet containing cholesterol (D12120101, Research Diets, Inc) supplemented with 10% w/v fructose in the drinking water (HFC+Fr diet) was provided to control and hepatocyte specific Pparg knockout male and female mice for 24 weeks. Both HFC+Fr-fed male and female mice developed obesity and insulin resistance. Only male mice developed clear signs of MASH with fibrosis. Hepatocyte specific Pparg had a significant effect in the regulation of hepatic transcriptomics in HFC+Fr-fed male mice.

2026-04-06 | GSE315007 | GEO

Hepatic transcriptome changes in testosterone-deficient pigs fed a high-fat diet

Project description:To gain insight into the role of testosterone in modulating hepatic fat accumulation, we collected liver tissues from high fat diet-fed intact male pigs, castrated male pigs, and castrated male pigs with testosterone replacement. RNA-Seq was employed to profile hepatic gene expression in pigs with different testosterone levels. Liver mRNA profiles of intact male pigs fed a HFC diet, castrated male pigs fed a HFC diet, and castrated male pigs treated with testosterone fed a HFC diet were generated by deep sequencing, using Illumina HiSeq 2000.

2015-01-08 | E-GEOD-62696 | biostudies-arrayexpress

Lower H2S-generating enzyme levels and persulfidation-mediated protein protection characterize metabolic dysfunction-associated steatohepatitis

Project description:Metabolic dysfunction–associated steatohepatitis (MASH), marked by hepatic steatosis and inflammation, is a major risk for cirrhosis and liver cancer. Obesity-induced oxidative stress plays a central role in MASH promoting protein damage and dysfunction. Cysteine persulfidation (PSSH), a post-translational modification regulated by hydrogen sulfide (H2S), is involved in protein stability and cellular protection. However, the role of PSSH in MASH is poorly understood. We found that H2S-producing enzymes are downregulated in livers with fibrosis and inflammation, leading to decreased hepatic PSSH. Using dimedone-switch-based mass spectrometry, we mapped the alterations in the liver persulfidome during diet-induced fibrosis and inflammation. While the levels of H2S-producing enzymes dropped, some proteins, including protein tyrosine phosphatases (PTPs) and redox regulators, showed increased PSSH. This change suggests that H2S-mediated persulfidation helps protect proteins from oxidative damage. Overall, decreased H2S enzyme expression and reduced PSSH may impair protection against oxidative stress, contributing to liver dysfunction in obesity.

2025-08-04 | PXD057932 | Pride

DIO-MASH mice analysed for hepatic gene expression after treatment with semaglutide

Project description:Modulation of metabolic, inflammatory, and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitis Metabolic dysfunction-associated steatohepatitis (MASH) is a chronic liver disease strongly associated with cardiometabolic risk factors. Semaglutide, a glucagon-like peptide-1 receptor agonist, improves liver histology in MASH, but the underlying signals and pathways driving semaglutide-induced MASH resolution are not well understood. We show that, in two preclinical MASH models, semaglutide improved histological markers of fibrosis and inflammation, and reduced hepatic expression of fibrosis- and inflammation-related gene pathways.

2025-04-25 | GSE294629 | GEO

CDA HFD mice analysed for hepatic gene expression after treatment with semaglutide

Project description:Metabolic dysfunction-associated steatohepatitis (MASH) is a chronic liver disease strongly associated with cardiometabolic risk factors. Semaglutide, a glucagon-like peptide-1 receptor agonist, improves liver histology in MASH, but the underlying signals and pathways driving semaglutide-induced MASH resolution are not well understood. We show that, in two preclinical MASH models, semaglutide improved histological markers of fibrosis and inflammation, and reduced hepatic expression of fibrosis- and inflammation-related gene pathways. NOTE: dose is 20 µg/kg QD as stated in the publication, not 10 nmol/kg as stated in the fastq file names!

2025-04-25 | GSE294630 | GEO

CITEseq of hepatic CD4+ T cells from healthy mice and mice with steatohepatitis

Project description:Unresolved inflammation and fibrosis are the two key features of metabolic dysfunction-associated steatohepatitis (MASH), a progressive form of steatotic liver disease that can evolve into cirrhosis and liver cancer. To better understand the role of CD4⁺ T cells in the pathogenesis of MASH, we comprehensively characterized hepatic CD4⁺ T cells in murine MASH at a single-cell protein and transcriptional level. CITE-sequencing revealed a marked shift in intrahepatic CD4⁺ T-cell composition in MASH, with enrichment of Th1, regulatory, and cytotoxic CD4⁺ T cells. Transcriptomic profiling also identified Tnfrsf4 (OX40) upregulation in hepatic CD4⁺ T cells during MASH. Together, these studies provide a proteogenomic single-cell atlas for hepatic CD4⁺ T cells and uncover a CD4⁺ T cell-dependent immunopathogenic circuit as a promising immunotherapeutic target to alleviate MASH and liver fibrosis.

2026-05-18 | GSE301733 | GEO

MIF-mediated crosstalk between Thrsp+ hepatocytes and Cd74+ lipid-associated macrophages in hepatic periportal zone drives MASH

Project description:Background & Aims: Spatial location of steatosis is closely related to the progression of metabolic dysfunction-associated steatohepatitis (MASH), and reports suggest lipid-associated macrophages (LAMs) facilitate this progression. However, the underling mechanisms remain elusive. Approach & Results: Spatial transcriptomics (ST) data revealed a significant increase in myeloid cells and MASH-related genes in the hepatic periportal (PP) zone of MASH mice, suggesting a vital role of PP zone in the MASH progression. Thrsp (Spot14), involved in fatty acid synthesis, was markedly elevated in the livers of MASH patients and mice. Notably, CellPhoneDB analysis identified strong interactions between Cd74 and macrophage migration inhibitory factor (MIF) within Thrsp-high zone. Furthermore, Thrsp, Cd74, Mif, Col3a1 and LAMs markers were prominently co-localized in hepatic PP zone of MASH mice, suggesting Thrsp-mediated crosstalk in this region played crucial role in MASH progression. Hepatic Thrsp overexpression/knockout experiments confirmed that Thrsp drove MASH progression by recruiting Cd74+ LAMs mediated by MIF. Mechanistically, Thrsp promoted hepatic palmitic acid (PA) synthesis, mainly by promoting hepatic de novo lipogenesis, and disturbing the binding of FASN-TRIM21, thereby inhibiting FASN’s ubiquitination. Cd74+ LAMs were activated and recruited by chemokine-like MIF secreted from hepatocytes and macrophages stimulated with PA. Additionally, the compound C6 identified as a Thrsp inhibitor, significantly ameliorated MASH in mice. Conclusions: Our study demonstrates that Thrsp drives MASH progression by recruiting Cd74+ LAMs mediated by MIF in hepatic PP zone, providing novel insights into the spatial zonation and crosstalk between lipogenic hepatocytes and LAMs that may result in novel therapies for MASH.

2025-12-05 | GSE293203 | GEO

Effects of engineered IL-18BP on attenuation of hepatic stellate cell activation

Project description:Metabolic dysfunction-associated steatohepatitis (MASH) is a chronic liver disease associated with hepatic inflammation and fibrosis. Inflammasome-mediated IL-18 signaling is enhanced under MASH condition. IL-18 binding protein (IL-18BP) is a soluble protein that can block IL-18 actions and therapeutic potential of IL-18BP for MASH-induced fibrosis is largely unknown. We newly developed a human IL-18BP biologics (APB-R3) and injected it to mice to evaluate its pharmacologic efficacy. APB-R3 strikingly abolished hepatic fibrosis and reduced collagen markers. We further investigated whether APB-R3 could inhibit fibrotic activation of hepatic stellate cells (HSCs). This study proposes that abrogation of IL-18 signaling by boosting IL-18BP can strongly inhibit the development of MASH-induced fibrosis and our engineered IL-18BP biologics can become promising therapeutic candidate for curing MASH.

2024-10-18 | GSE279499 | GEO

Hepatic sphingomyelin phosphodiesterase 3 promotes steatohepatitis by disrupting membrane sphingolipid metabolism

Project description:Metabolic dysfunction-associated steatohepatitis (MASH) remains a significant health challenge. Herein, we identify sphingomyelin phosphodiesterase 3 (SMPD3) as a key driver of hepatic ceramide accumulation through increasing sphingomyelin hydrolysis at the cell membrane. Hepatocyte-specific Smpd3 gene disruption and pharmacological inhibition of SMPD3 alleviate MASH, whereas reintroducing SMPD3 reverses the resolution of MASH. While healthy livers express low-level SMPD3, lipotoxicity-induced DNA damage suppresses SIRT1, triggering an upregulation of SMPD3 during MASH. This disrupts membrane sphingomyelin-ceramide balance and promotes MASH progression by enhancing caveolae-dependent lipid uptake in hepatocytes and extracellular vesicle secretion from steatotic hepatocytes to worsen inflammation and fibrosis. Thus, SMPD3 acts as a central hub integrating key MASH hallmarks. Notably, we discovered a bifunctional agent that simultaneously activates SIRT1 and inhibits SMPD3, which shows significant therapeutic potential in MASH treatment. These findings suggest that inhibition of hepatic SMPD3 restores membrane sphingolipid balance and holds great promise for developing novel MASH therapies.

2025-02-26 | GSE271336 | GEO

Hepatic sphingomyelin phosphodiesterase 3 promotes steatohepatitis by disrupting membrane sphingolipid metabolism

2025-02-26 | GSE271335 | GEO